Eisai 미래 성장

Future 기준 확인 3/6

Eisai (는) 각각 연간 7.9% 및 3.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 7.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 5.6% 로 예상됩니다.

주요 정보

7.9%

수익 성장률

7.93%

EPS 성장률

Pharmaceuticals 수익 성장	9.3%
매출 성장률	3.6%
향후 자기자본 수익률	5.57%
애널리스트 커버리지	Good
마지막 업데이트	19 May 2025

최근 미래 성장 업데이트

Here's What Analysts Are Forecasting For Eisai Co., Ltd. (TSE:4523) After Its Annual Results

May 18

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 11

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 12

Recent updates

Here's What Analysts Are Forecasting For Eisai Co., Ltd. (TSE:4523) After Its Annual Results

May 18

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Feb 11

Eisai (TSE:4523) Has Announced A Dividend Of ¥80.00

Jan 28

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Jan 14

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Jan 13

Eisai Co., Ltd.'s (TSE:4523) Share Price Matching Investor Opinion

Dec 26

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Dec 05

LEQEMBI's Global Expansion And Innovations Propel Revenue And Market Growth

Nov 25 LEQEMBI's global rollout in key regions is poised to drive significant revenue growth through market expansion and adoption.

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Nov 21

Earnings Troubles May Signal Larger Issues for Eisai (TSE:4523) Shareholders

Nov 15

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Nov 12

Is Eisai (TSE:4523) Using Too Much Debt?

Oct 15

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Sep 20

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Sep 05

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Aug 08

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Jul 25

Is Eisai (TSE:4523) A Risky Investment?

Jul 11

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Jul 11

Eisai Co., Ltd.'s (TSE:4523) P/E Is On The Mark

Jun 10

수익 및 매출 성장 예측

TSE:4523 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (JPY Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2028	839,942	58,132	67,200	74,081	10
3/31/2027	822,638	52,769	61,747	87,981	14
3/31/2026	800,789	46,950	43,980	86,517	11
3/31/2025	789,400	46,432	7,148	30,117	N/A
12/31/2024	791,660	58,792	1,672	18,856	N/A
9/30/2024	753,221	40,970	7,189	27,613	N/A
6/30/2024	733,845	32,648	13,901	34,771	N/A
3/31/2024	741,751	42,406	31,170	55,993	N/A
12/31/2023	749,460	45,421	35,701	61,925	N/A
9/30/2023	759,329	48,096	20,569	46,335	N/A
6/30/2023	757,075	48,874	-20,313	6,924	N/A
3/31/2023	744,402	55,432	-36,331	-1,772	N/A
12/31/2022	737,098	26,705	-17,149	18,648	N/A
9/30/2022	752,500	32,233	-8,913	30,329	N/A
6/30/2022	741,594	32,690	94,326	135,806	N/A
3/31/2022	756,226	47,954	77,123	117,590	N/A
12/31/2021	712,935	57,311	85,128	124,927	N/A
9/30/2021	691,250	62,508	80,215	123,618	N/A
6/30/2021	679,253	59,855	8,589	49,533	N/A
3/31/2021	645,942	42,119	35,709	73,853	N/A
12/31/2020	707,888	93,682	52,352	95,670	N/A
9/30/2020	713,400	120,571	77,080	112,990	N/A
6/30/2020	707,203	124,523	81,101	116,904	N/A
3/31/2020	695,621	121,767	52,556	102,782	N/A
12/31/2019	661,646	96,659	21,665	72,461	N/A
9/30/2019	631,974	57,725	12,273	62,240	N/A
6/30/2019	643,531	72,747	38,725	87,299	N/A
3/31/2019	642,834	63,386	76,092	103,714	N/A
12/31/2018	627,367	63,714	N/A	171,330	N/A
9/30/2018	625,106	65,679	N/A	186,973	N/A
6/30/2018	611,499	54,347	N/A	165,689	N/A
3/31/2018	600,054	51,845	N/A	149,649	N/A
12/31/2017	569,814	29,048	N/A	72,041	N/A
9/30/2017	554,276	30,269	N/A	61,644	N/A
6/30/2017	544,027	29,425	N/A	76,929	N/A
3/31/2017	539,097	39,358	N/A	75,851	N/A
12/31/2016	530,696	55,031	N/A	76,725	N/A
9/30/2016	542,313	71,812	N/A	78,627	N/A
6/30/2016	545,602	69,227	N/A	69,710	N/A
3/31/2016	547,922	54,933	N/A	95,617	N/A
12/31/2015	566,435	44,886	N/A	96,347	N/A
9/30/2015	554,912	43,871	N/A	82,653	N/A
6/30/2015	554,885	43,021	N/A	89,212	N/A
3/31/2015	548,465	43,254	N/A	76,022	N/A
12/31/2014	560,795	40,152	N/A	67,972	N/A
9/30/2014	561,938	15,717	N/A	81,637	N/A
6/30/2014	578,945	29,225	N/A	81,339	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 4523 의 연간 예상 수익 증가율( 7.9% )이 saving rate( 0.5% 보다 높습니다. ).

수익 vs 시장: 4523 의 연간 수익( 7.9% ) JP 시장( 7.6% 보다 빠르게 성장할 것으로 예상됩니다. 7.6% 연간).

고성장 수익: 4523 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: 4523 의 수익(연간 3.6% ) JP 시장( 3.6% 보다 빠르게 성장할 것으로 예상됩니다. 3.6% 연간).

고성장 수익: 4523 의 수익(연간 3.6% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 4523 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 5.6 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/05/22 12:57
장 마감 주가	2025/05/22 00:00
수익	2025/03/31
연간 수익	2025/03/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Eisai Co., Ltd. 25 애널리스트 중 14 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Atsushi Seki	Barclays
Koichi Mamegano	BofA Global Research
Aaron Ho	CFRA Equity Research

Eisai 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Consensus EPS estimates fall by 11%

Here's What Analysts Are Forecasting For Eisai Co., Ltd. (TSE:4523) After Its Annual Results

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Price target decreased by 7.7% to JP¥6,103

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Consensus EPS estimates increase by 10%, revenue downgraded

Recent updates

Consensus EPS estimates fall by 11%

Here's What Analysts Are Forecasting For Eisai Co., Ltd. (TSE:4523) After Its Annual Results

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Eisai Co., Ltd., Annual General Meeting, Jun 18, 2025

Eisai Co., Ltd. (TSE:4523) completed the acquisition of EcoNaviSta, Inc. (TSE:5585) from a group of shareholders.

MHRA to Evaluate Monthly Intravenous Maintenance Dosing of Leqembi®? for the Treatment of Early Alzheimer's Disease in the UK

Is Eisai (TSE:4523) A Risky Investment?

Eisai Co., Ltd. and Biogen Inc. Announces Leqemab Marketing Authorization in the European Union

Upcoming dividend of JP¥80.00 per share

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Eisai Co., Ltd. to Report Q2, 2026 Results on Nov 05, 2025

Eisai Co., Ltd. to Report Fiscal Year 2025 Results on May 15, 2025

Eisai (TSE:4523) Will Pay A Dividend Of ¥80.00

Eisai Co., Ltd. and Biogen Inc. Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

Now 20% undervalued after recent price drop

Eisai (TSE:4523) Will Pay A Dividend Of ¥80.00

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Third quarter 2025 earnings: EPS and revenues exceed analyst expectations

Now 20% undervalued after recent price drop

Eisai (TSE:4523) Has Announced A Dividend Of ¥80.00

Eisai Co., Ltd. and Biogen Inc. Announce FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Eisai Announces FDA Approval for Leqembi in US

Merck and Eisai Provide Update on Phase 3 LEAP-015 Trial Evaluating KEYTRUDA (Pembrolizumab) Plus LENVIMA (Lenvima) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma

Price target decreased by 7.7% to JP¥6,103

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Eisai Co., Ltd. and Biogen Inc. Announces FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease

Here's Why Eisai (TSE:4523) Can Manage Its Debt Responsibly

Eisai Co., Ltd.'s (TSE:4523) Share Price Matching Investor Opinion

Eisai Co., Ltd. and Biogen Inc. Announces Approval of ''LEQEMBI" (Lecanemab) for the Treatment of Early Alzheimer's Disease in Mexico

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Eisai Launches Leqembi in South Korea

LEQEMBI's Global Expansion And Innovations Propel Revenue And Market Growth

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

First half dividend of JP¥80.00 announced

Earnings Troubles May Signal Larger Issues for Eisai (TSE:4523) Shareholders

Eisai Co., Ltd. and Biogen Inc. Receive Positive Opinion from CHMP in European Union for Lecanemab in Early Alzheimer’s Disease

Results: Eisai Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Eisai Completes Rolling BLA Submission for Subcutaneous Maintenance Dosing of Leqembi® (lecanemab-irmb) in the US

Eisai Co., Ltd. and Biogen Inc. Completes Rolling Submission to US FDA for LEQEMBI Biologics License Application for Subcutaneous Maintenance Dosing

Eisai Co., Ltd. Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference

Is Eisai (TSE:4523) Using Too Much Debt?

Upcoming dividend of JP¥80.00 per share

Eisai (TSE:4523) Is Paying Out A Dividend Of ¥80.00

Merck and Eisai Announce Results from the First Interim Analysis of the Phase 3 LEAP-012 Trial Evaluating KEYTRUDA® (Pembrolizumab)

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Eisai Co., Ltd. Accelerates Progress in Oncology Research with New Data At Esmo Congress 2024

BioArctic AB (Publ) Partner Eisai Announces Leqembi (Lecanemab) Authorized for Early Alzheimer's Disease in Great Britain

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

New minor risk - Earnings quality

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorates as stock falls 17%

Eisai Co., Ltd. and Biogen Inc. Announces New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting Leqemab (Lecanemab-Irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at the Alzheimer's Association International Conference

New minor risk - Share price stability

Eisai Provides Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union

Eisai (TSE:4523) Is Due To Pay A Dividend Of ¥80.00

Eisai Co. Ltd Announces To Present Latest Findings on Its Alzheimer's Disease Pipeline and Research

Eisai Announces Approval for the Treatment of Alzheimer's Disease in Israel

Is Eisai (TSE:4523) A Risky Investment?

Eisai (TSE:4523) Has Affirmed Its Dividend Of ¥80.00

Final dividend of JP¥80.00 announced

High number of new directors

Eisai Co., Ltd. and Biogen Inc. Announces Launch of Leqembi in China

Full year 2024 earnings: EPS exceeds analyst expectations

Eisai Co., Ltd.'s (TSE:4523) P/E Is On The Mark

Consensus EPS estimates increase by 10%, revenue downgraded

Eisai Co., Ltd. (TSE:4523) announces an Equity Buyback for 6,500,000 shares, representing 2.26% for ¥30,000 million.

Full year 2024 earnings: EPS exceeds analyst expectations

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status